Noninvasive prenatal DNA testing is the vanguard of genomic medicine. In only four years,
this screening test has revolutionized prenatal care globally and opened up new prospects …

Noninvasive prenatal testing for fetal aneuploidy using cell-free DNA has been widely
integrated into routine obstetrical care. The scope of cell-free DNA testing has expanded …

Background Current cell-free DNA assessment of fetal chromosomes does not analyze and
report on all chromosomes. Hence, a significant proportion of fetal chromosomal …

Objectives Embryonic numerical and structural chromosomal abnormalities are the most
common cause of early pregnancy loss. However, the role of submicroscopic copy‐number …

Objective In this study, we expanded conventional cell‐free fetal DNA (cfDNA)‐based non‐
invasive prenatal testing (NIPT) to cover the entire genome. We aimed to compare the …

Background Noninvasive prenatal testing (NIPT) for fetal aneuploidies by scanning cell-free
fetal DNA in maternal plasma is rapidly becoming a first-tier aneuploidy screening test in …

Objective The goal was to develop methods for detection of chromosomal and
subchromosomal abnormalities in fetal cells in the mother's circulation at 10–16 weeks' …

Purpose To evaluate the diagnostic yield of chromosomal microarray (CMA) in pregnancies
with normal ultrasound. Methods This retrospective cohort analysis included all pregnancies …

Background: Cell-free nuclear DNA has been isolated from spent embryo culture medium.
Whether this small amount of DNA can be amplified at the whole genome level and the …

Non‐invasive prenatal testing (NIPT) based on cell‐free DNA in maternal plasma is being
expanded to include additional chromosome abnormalities beyond those involving …